Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Rainer K. Brachmann"'
Publikováno v:
Cancer Informatics, Vol 2, Pp 277-287 (2006)
Complex problems in life science research give rise to multidisciplinary collaboration, and hence, to the need for heterogeneous database integration. The tumor suppressor p53 is mutated in close to 50% of human cancers, and a small drug-like molecul
Externí odkaz:
https://doaj.org/article/864d111cb41e4602ba315dc5963c3c38
Autor:
Mark R. Lackner, David S. Shames, Lukas C. Amler, Garret M. Hampton, Leanne Ross, Lori S. Friedman, Deepak Sampath, Sankar Mohan, Ajay Pandita, Peter M. Haverty, Rainer K. Brachmann, Jane Fridlyand, Hartmut Koeppen, Ling Huw, Carol O'Brien, Jill M. Spoerke
Purpose: Class 1 phosphatidylinositol 3-kinase (PI3K) plays a major role in cell proliferation and survival in a wide variety of human cancers. Here, we investigated biomarker strategies for PI3K pathway inhibitors in non–small-cell lung cancer (NS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bb9f1ef4c3426577829c8470390f8ee
https://doi.org/10.1158/1078-0432.c.6522099
https://doi.org/10.1158/1078-0432.c.6522099
Autor:
Mark R. Lackner, David S. Shames, Lukas C. Amler, Garret M. Hampton, Leanne Ross, Lori S. Friedman, Deepak Sampath, Sankar Mohan, Ajay Pandita, Peter M. Haverty, Rainer K. Brachmann, Jane Fridlyand, Hartmut Koeppen, Ling Huw, Carol O'Brien, Jill M. Spoerke
PDF file - 110K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cd35abb90f0547628e08dea87f9b123
https://doi.org/10.1158/1078-0432.22451103.v1
https://doi.org/10.1158/1078-0432.22451103.v1
Autor:
Mark R. Lackner, David S. Shames, Lukas C. Amler, Garret M. Hampton, Leanne Ross, Lori S. Friedman, Deepak Sampath, Sankar Mohan, Ajay Pandita, Peter M. Haverty, Rainer K. Brachmann, Jane Fridlyand, Hartmut Koeppen, Ling Huw, Carol O'Brien, Jill M. Spoerke
XLSX file - 17K, PI3K pathway alterations in NSCLC cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c9708b75c16b3d3da84a0342bf27834
https://doi.org/10.1158/1078-0432.22451097.v1
https://doi.org/10.1158/1078-0432.22451097.v1
Autor:
Mark R. Lackner, David S. Shames, Lukas C. Amler, Garret M. Hampton, Leanne Ross, Lori S. Friedman, Deepak Sampath, Sankar Mohan, Ajay Pandita, Peter M. Haverty, Rainer K. Brachmann, Jane Fridlyand, Hartmut Koeppen, Ling Huw, Carol O'Brien, Jill M. Spoerke
XLSX file - 18K, PI3K pathway alterations in NSCLC FFPE tumor samples
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11ccae2bd3308c4df76e7c9e2d188d54
https://doi.org/10.1158/1078-0432.22451100.v1
https://doi.org/10.1158/1078-0432.22451100.v1
Autor:
Mark R. Lackner, David S. Shames, Lukas C. Amler, Garret M. Hampton, Leanne Ross, Lori S. Friedman, Deepak Sampath, Sankar Mohan, Ajay Pandita, Peter M. Haverty, Rainer K. Brachmann, Jane Fridlyand, Hartmut Koeppen, Ling Huw, Carol O'Brien, Jill M. Spoerke
PDF file - 221K, S1 Selected regions of recurrent amplification in 52 NSCLC tumor samples profiled by array CGH; S2 (A), GISTIC analysis showing combined frequency and magnitude of PIK3CA amplification in NSCLC tumor samples with squamous (upper) or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f52eff6ec27bddd616f1c9e70bcb889
https://doi.org/10.1158/1078-0432.22451106
https://doi.org/10.1158/1078-0432.22451106
Autor:
Steven J. Cohen, Safi Shahda, Colin D. Weekes, Efrat Dotan, Bert H. O'Neil, Shailaja Uttamsingh, Dana Backlund Cardin, Wells A. Messersmith, Ann M. Kapoun, Crystal S. Denlinger, Igor Astsaturov, Robert Joseph Stagg, Heinz-Josef Lenz, Rainer K. Brachmann
Publikováno v:
Clin Cancer Res
Purpose: The recombinant fusion protein ipafricept blocks Wnt signaling, and in combination with gemcitabine and nab-paclitaxel caused tumor regression in xenografts. This phase Ib study evaluated the combination of ipafricept with nab-paclitaxel + g
Autor:
Randall Henner, Azeez Farooki, Carlos Becerra, Joyce O'Shaughnessy, Shailaja Uttamsingh, Donald A. Richards, Rainer K. Brachmann, Cynthia Osborne, Ann M. Kapoun, Chun Zhang, Jennifer R. Diamond, Lu Xu, Alain C. Mita, Bob Stagg, Monica M. Mita
Publikováno v:
Breast Cancer Res Treat
Vantictumab is a monoclonal antibody that binds to frizzled (FZD) receptors and inhibits canonical WNT signaling. This phase Ib dose escalation study enrolled patients with locally recurrent or metastatic HER2-negative breast cancer who were treated
Autor:
Rainer K. Brachmann, David Smith, Antonio Jimeno, Michael S. Gordon, David S. Mendelson, Ann M. Kapoun, Jakob Dupont, Shailaja Uttamsingh, Robert Joseph Stagg, Wells A. Messersmith, Lu Xu, Rashmi Chugh
Publikováno v:
Clinical Cancer Research. 23:7490-7497
Purpose: Wnt signaling is implicated in tumor cell dedifferentiation and cancer stem cell function. Ipafricept (OMP-54F28) is a first-in-class recombinant fusion protein with the extracellular part of human frizzled 8 receptor fused to a human IgG1 F
Autor:
Lia Gore, Rainer K. Brachmann, Anthony W. Tolcher, Ron Yu, L. Mason Shih, Muralidhar Beeram, Colin D. Weekes, Priti S. Hegde, Hong Xiang, Kyriakos P. Papadopoulos, Yan Xin, Amita Patnaik
Publikováno v:
Investigational New Drugs. 32:653-660
The human monoclonal antibody MNRP1685A targets the VEGF binding domain of neuropilin-1 (NRP1), a multi-domain receptor necessary for neural development and blood vessel maturation. In nonclinical studies, MNRP1685A prevents vascular maturation by ke